Likhami Consulting provides business advisory services including project feasibility studies, financial consultancy, and market research to corporate clients and non-governmental organizations.
The company lacks a durable competitive advantage, as evidenced by negative average return on capital employed and high net losses. There is no evidence of proprietary technology, high switching costs, or a dominant brand that allows for excess returns in the fragmented consulting market.
Management has primarily focused on conserving resources and maintaining a small investment portfolio rather than reinvesting in growth or returning capital to shareholders. The lack of dividends and stagnant operations suggest a failure to generate value from the existing capital base.
The company's slow-motion collapse was driven by its persistent inability to generate a positive return on capital, eventually exhausting its remaining cash reserves. While management focused on administrative shuffling and office relocations, the core consulting business remained a shell with no scale. The disconnect between the soaring stock price and the dismal underlying financials finally corrected when the lack of liquidity prevented any exit for minority shareholders, leaving them holding shares in a stagnant entity that failed to justify its existence as a public company.
RichFakir rates Likhami Consulting Ltd's business quality as poor — 29/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Likhami Consulting Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Likhami Consulting Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Likhami Consulting Ltd's fair value is about ₹1 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →